Antibodies to CD40 with enhanced agonist activity
Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD 40 . Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
1. An isolated antibody or antigen binding portion thereof that specifically binds to human CD40 comprising:
the CDRs of antibody 12D6-24 wherein CDRH 1, CDRH2 and CDRH3 comprise residues 31-35, 50-66 and 99-108, respectively, of SEQ ID NO: 12 and CDRL1, CDRL2 and CDRL3 comprise residues 24-39, 55-61 and 94-102, respectively, of SEQ ID NO: 9, wherein the antibody further comprises an Fc region modified to enhance specificity of binding to FcγRIIb, wherein the Fc region comprises a sequence selected from the group consisting of SE (SEQ ID NO: 66), SELF (SEQ ID NO: 67), P238D (SEQ ID NO: 68), V4 (SEQ ID NO: 69), V4 D270E (SEQ ID NO: 70), V7 (SEQ ID NO: 71), V8 (SEQ ID NO: 72), V9 (SEQ ID NO: 73), V9 D270E (SEQ ID NO: 74), V11 (SEQ ID NO: 75), and V12 (SEQ ID NO: 76).
2. The antibody of claim 1 comprising:
the heavy and light chain variable regions of antibody 12D6-24 comprising residues 1-119 and 1-112 of SEQ ID NO: 12 and SEQ ID NO: 9, respectively.
3. The antibody of claim 1 exhibiting an A/I ratio of less than 5.
4. The antibody of claim 3 exhibiting an A/I ratio of less than 1.
5. The antibody of claim 1 comprising heavy and light chain sequences selected from the groups consisting of:
a) the heavy and light chains of antibody 12D6-24-P238D comprising the sequences of SEQ ID NO:13 and SEQ ID NO:9, respectively;
b) the heavy and light chains of antibody 12D6-24-SE comprising the sequences of SEQ ID NO:14 and SEQ ID NO:9, respectively;
c) the heavy and light chains of antibody 12D6-24-SELF comprising the sequences of SEQ ID NO:15 and SEQ ID NO:9, respectively;
d) the heavy and light chains of antibody 12D6-24-V4 comprising the sequences of SEQ ID NO:16 and SEQ ID NO:9, respectively;
e) the heavy and light chains of antibody 12D6-24-V4 D270E comprising the sequences of SEQ ID NO:17 and SEQ ID NO:9, respectively;
f) the heavy and light chains of antibody 12D6-24-V8 comprising the sequences of SEQ ID NO:18 and SEQ ID NO:9, respectively;
g the heavy and light chains of antibody 12D6-24-V9 comprising the sequences of SEQ ID NO:19 and SEQ ID NO:9, respectively;
h) the heavy and light chains of antibody 12D6-24-V9 D270E comprising the sequences of SEQ ID NO:20 and SEQ ID NO:9, respectively;
i) the heavy and light chains of antibody 12D6-24-V11 comprising the sequences of SEQ ID NO:21 and SEQ ID NO:9, respectively; and
j) the heavy and light chains of antibody 12D6-24-V12 comprising the sequences of SEQ ID NO:22 and SEQ ID NO:9, respectively.
6. A pharmaceutical composition comprising:
a) the antibody, or antigen binding portion thereof, of claim 1 ; and
b) a carrier.
7. A method of stimulating a T-cell mediated immune response in a subject comprising administering to the subject the pharmaceutical composition of claim 6 .
8. The method of claim 7 , wherein the subject has a cancer and a T-cell mediated immune response against the cancer is stimulated.
9. The method of claim 7 , wherein the subject has a chronic viral infection and a T-cell mediated immune response against the viral infection is stimulated.
10. The method of claim 8 , wherein the cancer is selected from the group consisting of: bladder cancer, breast cancer, uterine/cervical cancer, ovarian cancer, prostate cancer, testicular cancer, esophageal cancer, gastrointestinal cancer, pancreatic cancer, colorectal cancer, colon cancer, kidney cancer, head and neck cancer, lung cancer, stomach cancer, germ cell cancer, bone cancer, liver cancer, thyroid cancer, skin cancer, neoplasm of the central nervous system, lymphoma, leukemia, myeloma, sarcoma, and virus-related cancer.